Sativex associated with behavioral-relapse prevention strategy as treatment for cannabis dependence: A case series

Journal of Addiction Medicine

Volumn 10, Issue 4, 2016, Pages 274-279

  Trigo, Jose M ^a   Soliman, Alexandra ^a   Staios, Gregory ^a   Quilty, Lena ^b   Fischer, Benedikt ^c,d,e,g   George, Tony P ^a,d   Rehm, Jürgen ^c,d,e,f   Selby, Peter ^a,d,e   Barnes, Allan J ^h   Huestis, Marilyn A ^h   Le Foll, Bernard ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b Clinical Research   (Canada)

^c Social and Epidemiological Research Department   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g SIMON FRASER UNIVERSITY   (Canada)

^h NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Abstinence; cannabidiol; cannabis; marijuana; THC; withdrawal

Indexed keywords

CANNABIS; NABIXIMOLS; PLANT EXTRACT; TETRAHYDROCANNABINOL-CANNABIDIOL COMBINATION;

ADULT; ARTICLE; BEHAVIOR ASSESSMENT; BEHAVIOR THERAPY; CANNABIS ADDICTION; CLINICAL ARTICLE; COGNITIVE BEHAVIORAL THERAPY; COMMON COLD; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HELP SEEKING BEHAVIOR; HUMAN; MALE; MOTIVATIONAL ENHANCEMENT THERAPY; NAUSEA; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RASH; SCORING SYSTEM; SELF REPORT; SLEEP DISORDER; WITHDRAWAL SYNDROME; XEROSTOMIA; CLINICAL TRIAL; COGNITIVE THERAPY; MARIJUANA ABUSE; MIDDLE AGED; MOTIVATIONAL INTERVIEWING; MULTIMODALITY CANCER THERAPY; PILOT STUDY; PROCEDURES; RECURRENT DISEASE; SECONDARY PREVENTION;

ADULT; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; MOTIVATIONAL INTERVIEWING; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; PLANT EXTRACTS; RECURRENCE; SECONDARY PREVENTION;

EID: 84982797307     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0000000000000229     Document Type: Article

References (28)

1. Allsop DJ, Copeland J, Lintzeris N, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry 2014; 71: 281-291
2. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994; 2: 244-268
3. Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999; 94: 1311-1322
4. Budney AJ, Roffman R, Stephens RS, et al. Marijuana dependence and its treatment. Addict Sci Clin Pract 2007; 4: 4-16
5. Crime UNOoDa (2010). World Drug Report. Vienna, Austria 2010
6. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558-1572
7. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57: 594-608
8. D'Souza DC, Ranganathan M, Braley G, et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008; 33: 2505-2516
9. Elkashef A, Vocci F, Huestis M, et al. Marijuana neurobiology and treatment. Subst Abus 2008; 29: 17-29
10. Guimaraes FS, Chiaretti TM, Graeff FG, et al. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 1990; 100: 558-559
11. Heishman SJ, Singleton EG, Liguori A. Marijuana Craving Questionnaire: development and initial validation of a self-report instrument. Addiction 2001; 96: 1023-1034
12. Karschner EL, Darwin WD, McMahon RP, et al. Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther 2011; 89: 400-407
13. Lev-Ran S, Le Strat Y, Imtiaz S, et al. Gender differences in prevalence of substance use disorders among individuals with lifetime exposure to substances: results from a large representative sample. Am J Addict 2013; 22: 7-13
14. Lowe RH, Karschner EL, Schwilke EW, et al. Simultaneous quantification of delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. J Chromatogr A 2007; 1163: 318-327
15. Marshall K, Gowing L, Ali R, et al. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev 2014; 12: CD008940
16. Mason BJ, Crean R, Goodell V, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012; 37: 1689-1698
17. McPartland JM, Duncan M, Di Marzo V, et al. Are cannabidiol and Delta(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system?. A systematic review. Br J Pharmacol 2015; 172: 737-753
18. Nordstrom BR, Levin FR. Treatment of cannabis use disorders: a review of the literature. Am J Addict 2007; 16: 331-342
19. Parker LA, Burton P, Sorge RE, et al. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaineinduced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl) 2004; 175: 360-366
20. Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 2008; 13: 147-159
21. Prud'homme M, Cata R, Jutras-Aswad D. Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence. Subst Abuse 2015; 9: 33-38
22. Ren Y, Whittard J, Higuera-Matas A, et al. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci 2009; 29: 14764-14769
23. Schwope DM, Scheidweiler KB, Huestis MA. Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2011; 401: 1273-1283
24. Sobell LC, Sobell MB, Leo GI, et al. Reliability of a timeline method: assessing normal drinkers? reports of recent drinking and a comparative evaluation across several populations. Br J Addict 1988; 83: 393-402
25. Trigo JM, Lagzdins D, Rehm J, et al. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend 2016. In Press
26. Vandrey R, Haney M. Pharmacotherapy for cannabis dependence: how close are we?. CNS Drugs 2009; 23: 543-553
27. Volkow ND, Baler RD, Compton WM, et al. Adverse health effects of marijuana use. N Engl J Med 2014; 370: 2219-2227
28. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006; 39: 421-429